COGT Earnings Preview: Options Bullishness Hits New Extreme

Cogent Biosciences heads into its August 13 print with the most call-skewed options market in a year — but a 10% short base and a November FDA decision that dwarfs anything the quarterly numbers can deliver.

The options picture has grown more extreme since the previous note two days ago. The put/call ratio has dropped further to 0.2133, now exactly the 52-week low and more than two standard deviations below its 20-day average of 0.27. That reading is not noise. It reflects a market positioning aggressively for upside, almost certainly driven by the November 30 PDUFA date for bezuclastinib in GIST rather than anything in Thursday's financials. The stock rose 6.9% on the week before pulling back 2% on Monday to close at $41.53 — a move that looks like profit-taking ahead of the report rather than a shift in sentiment. Peers ORIC and PVLA gained 22% and 13.5% respectively on the week, suggesting the broader small-cap biotech tape has been strong rather than this being idiosyncratic COGT flow.

The short position complicates that bullish read. At 10.2% of the free float — roughly 15.5 million shares — shorts have not retreated meaningfully despite the call surge. Short interest has edged up about 4% over the past month and ticked marginally higher again last Friday. The borrow market, however, gives no signal of stress: availability is ample at 751%, cost to borrow is just 0.54%, and both figures have been stable. Shorts are not being squeezed and are not paying up to hold the position. That combination — extreme call skew alongside a sticky short base at low borrow cost — points to a two-sided bet on the PDUFA outcome rather than a uniform directional view.

The analyst community is uniformly constructive, with all eight active ratings at buy or outperform and a mean price target around $55 against the current $41.53. HC Wainwright raised its target to $55 after the May earnings print; Jefferies initiated at Buy with a $55 target in March. The bull case centres on the FDA's priority review acceptance and the estimated $9.4 billion addressable market for bezuclastinib if approved. Bears point to the company's deeply negative operating metrics — EV/EBITDA near -27, negative EPS yield — and the execution risk inherent in a pre-commercial biotech with a single binary catalyst on the calendar.

The August 13 print is therefore a holding point rather than a turning point: what it tests is whether the company's cash runway and pipeline progress give the market enough confidence to sustain the current valuation through the four months remaining before the FDA delivers its verdict.